VKTX earnings analysis
What we found in VKTX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Viking Therapeutics reported zero revenue for Q1 2026, missing estimates significantly with an actual EPS of -1.37, compared to an estimate of -0.92. Clinical expenses drove losses as the company remains focused on the ongoing development of its lead drug candidates, but risks related to trial outcomes persist, impacting investor sentiment.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Zero Revenue Reported
- Viking reported actual revenue of $0.0 for Q1 2026, missing expectations.
- EPS Miss
- The reported EPS was -1.37, deviating from the estimated -0.92.
- Continued Clinical Focus
- Management continues to develop VK2735 and VK2809 despite financial losses.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Wider Losses
- The Q1 EPS loss deepened to -1.37 compared to -1.39 in Q4 2025.
- Cash Decrease
- Cash and cash equivalents decreased to $118.116 million from $165.810 million at year-end 2025.
- Higher Clinical Expenses
- Total clinical study expenses rose to $103.2 million in Q1, contributing to financial strain.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.37
What they said about what is next.
No changes made to financial guidance; focus remains on trial timelines.
The filing reads worse than the one before it.
What came before.
- 10-K · February 11, 2026
- Viking Therapeutics positions itself as a clinical-stage metabolic and endocrine drug developer focused on VK2735 (GLP-1/GIP dual agonist) and TRß programs (VK2809, VK0214). The 10-K documents multiple positive clinical…
- 10-Q · October 23, 2025
- Viking reported Q3 2025 net loss of $90.8M (basic/diluted loss per share $0.81) on no revenue; R&D spend surged to $89.95M in the quarter driving operating loss of $98.56M. Cash and short-term investments remain large…
- 10-Q · July 24, 2024
- Viking Therapeutics reported no revenue and a Q2 net loss of $22.25 million (basic and diluted net loss per share $0.20) as R&D and G&A ramped. The quarter reflects a significant financing-driven liquidity increase…
- 10-Q · October 25, 2023
- Viking Therapeutics reported a net loss of $22.534 million for Q3 2023, widening from a loss of $15.773 million in Q3 2022. The diluted earnings per share (EPS) came in at $(0.23), slightly below the consensus estimate…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing VKTX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever